SuperNova DiagnosticsÂ® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
WASHINGTON, LONDON and HONG KONG, Nov. 22, 2011 /PRNewswire/ –SuperNova DiagnosticsÃ‚®, Inc., a privately-held global diagnostics company for human and non-human health applications, announced that Neil J. Campbell, President and CEO, will be presenting at the 23rd Annual Piper Jaffray Healthcare Conference on November 30, 2011 at 10:30 a.m. ET at the New York Palace – 455 Madison Avenue, New York.
The presentation will include an overview of SuperNova’s proprietary point-of-care (POC) and point-of-use (POU) diagnostic technology and additional details on the company’s recent commercial partnership with Concile, GmbH.
Mr. Campbell stated, “Demand for SuperNova’s AmpCrystalÃ‚® platform is rapidly accelerating, both in the field, as evidenced by our recent commercial partnership with Concile, and among industry and investment professionals. The Piper Jaffray Healthcare Conference provides an ideal forum for reaching this latter group and to showcase the diagnostic and revenue potential of our POC/POU technology.”
About SuperNova DiagnosticsÃ‚®, Inc.
SuperNovaÃ‚® is a development-stage diagnostics company with a proprietary platform for conducting diagnostics at the site of interest with point-of-care in human health and point-of-use for non-human health applications. A powerful proprietary nanochemistry, AmpCrystalÃ‚®, can deliver novel, next generation performance for pathogens, proteins, and directly measure DNA without PCR with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements. SuperNova can be utilized in a wide range of diagnostic formats (lateral flow, self-contained cartridges, microtitre, microarrays, closed systems, research products and OEM). SuperNovaÃ‚® — Putting the Laboratory in the Palm of Your HandÃ‚®. For additional information, please visit www.supernovadiagnostics.com.
SOURCE SuperNova Diagnostics(R), Inc.